Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Perianne Boring McNulty, a director of Kindly MD, Inc. (NAKA), reported acquiring 112,781 restricted stock units on 09/22/2025. The RSUs were granted at a $0 price and are scheduled to vest on August 15, 2026, subject to her continued service on the company's board through the vesting date. After this transaction the reporting person beneficially owns 112,781 shares in a direct ownership form. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Kindly MD, Inc. (NAKA) director Charles Phillip Blackburn was granted 112,781 restricted stock units (RSUs) on 09/22/2025, recorded on a Form 4 filed 09/24/2025. The RSUs carry a $0 purchase price and are reported as directly beneficially owned following the grant.
The RSUs are subject to time-based vesting and will vest on August 15, 2026 provided Blackburn continues to serve on the company’s board through that Vesting Date. After the reported transaction, Blackburn is shown as beneficial owner of 112,781 shares tied to these RSUs.
Kindly MD, Inc. reported that on September 15, 2025 it sent a redemption notice to the holder of its Secured Convertible Debenture dated August 15, 2025. The company plans to redeem on September 29, 2025 all amounts under the debenture that have not been converted by that date, paying cash equal to 100% of the outstanding principal plus a 1.5% payment premium, with payment to be delivered on September 30, 2025. If the holder does not convert any portion of the debenture, the total cash redemption amount including the 1.5% premium would be $203,000,000, and there will be no accrued or unpaid interest due as of the redemption date.
Kindly MD, Inc. filed an 8-K to share a letter it sent to shareholders on September 15, 2025. In the letter, the company explains that it filed a Form S-3 registration statement on September 12, 2025, which is a document that can allow it to sell securities or register securities for resale in the future. The company notes that it expects its share price volatility to increase for a period of time and reiterates its focus on its long-term vision. The shareholder letter is attached as Exhibit 99.1 and is furnished under a Regulation FD disclosure, meaning it is not treated as filed for liability purposes under Section 18 of the Exchange Act.
Kindly MD, Inc. discloses material risks and shareholder details in this S-3ASR filing. The company warns that costs and potential litigation related to a proposed Merger have been and will be incurred, that trading of its securities may be volatile, and that shareholders may face dilution from warrant exercises and future equity issuances. The filing highlights industry-specific regulatory risk for medical cannabis, competitive and technology threats, reliance on key management, and cybersecurity concerns. Significant beneficial ownership stakes are shown, including a holder with 133,928,571 shares (27.19%) and another with 114,246,002 shares (23.94%), and a large block totaling 53,571,429 shares (13.57%). The registrant describes permitted distribution methods for registered shares and undertakes post-effective filing obligations. The document includes officer and director signatures certifying the filing.
Kindly MD, Inc. filed an 8-K reporting current beneficial ownership information for its common stock and tradeable warrants. The filing lists individual holdings for directors and executive officers and aggregates that all officers and directors as a group hold 21,798,017 shares, representing 5.80% of the outstanding common stock. It also discloses a significant institutional holder, Verition Multi-Strategy Master Fund Ltd., owning 37,781,847 shares, equal to 9.99% of the company. The filing is a routine ownership disclosure showing insider positions and a near-10% outside stake, without other transaction, financial performance, or management-change detail.
Kindly MD, Inc. (NAKA) filed an S-3ASR describing securities offerings, post‑merger capital changes and risk factors. The filing discloses the company may use proceeds for a Bitcoin Treasury Strategy, working capital, debt repayment, acquisitions, capital expenditures, projects or share repurchases. It lists detailed terms that may govern future debt securities, warrants, rights and units. The company warns of costs and potential litigation from the Merger, post‑closing volatility in its stock, future dilution from outstanding warrants, a convertible debenture and PIPE issuances, operational and regulatory risks (including implementing a bitcoin treasury operation and crypto regulation risks), and cyber and IP risks. The Registrant states its common stock trades on Nasdaq under NAKA and references recent SEC filings and exhibits that update its capital stock description.
Kindly MD, Inc. filed an amended Current Report (Form 8-K/A) that attaches exhibit-level disclosures for Nakamoto Holdings, Inc. The filing identifies the company's trading symbols as NAKA on The Nasdaq Stock Market LLC and NAKAW on the OTC Pink Market. It includes the consent of Wolf & Company, P.C., audited financial statements of Nakamoto as of April 30, 2025 and for the period from March 6, 2025 (inception) to April 30, 2025, unaudited financials as of June 30, 2025, unaudited pro forma condensed combined financial statements reflecting the acquisition of Nakamoto, supplemental risk factors, and management discussion and analysis for the stated periods. The filing is executed by CEO David Bailey.
Tyler Matthew Evans, identified as Chief Investment Officer and a director of Kindly MD, Inc. (NAKA), reported on Form 4 that on 08/14/2025 he acquired 2,232,114 shares of the issuer’s common stock at a reported price of $0, increasing his total beneficial ownership to 2,410,685 shares. The filing is signed on 08/22/2025. The form shows a non-derivative acquisition only and provides no additional explanatory detail about the mechanics or consideration for the transaction.
Kindly MD, Inc. (NAKA) Form 3: Tyler Matthew Evans filed an initial Form 3 disclosing direct beneficial ownership of 178,571 shares of Kindly MD common stock. The filing lists Evans as a Director, an Officer (Chief Investment Officer), and not a 10% owner. The Form 3 reports the event date of 08/14/2025 and is signed on 08/22/2025.